Sep 19, 2011 — Accelr8 Technology Corporation (NYSE Amex: AXK) announced results presented at the 51st ICAAC held in Chicago on September 17. As previously announced in July, the presenters received an award for an "outstanding presentation of an abstract accepted by ICAAC."
Jul 28, 2011 — Favorable data review followed by project to install newest version of BACcel™ automation in collaborator's microbiology lab.
Jul 18, 2011 — ICAAC's Program Committee recognizes Accelr8's BACcel™ rapid diagnostic system as a significant advance in Clinical Microbiology.
Jun 30, 2011 — Accelr8 extends current agreement to allow time for data evaluation. Intent to reach terms by July 31.
May 23, 2011 — Accelr8 presented results of two studies at ASM 2011 in New Orleans. One reported results with a new 4-hour hVISA test for a threatening new type of Staph resistance. The second study screened ICU patient specimens to successfully detect and identify three leading species of potentially resistant pathogens in 4 hours, directly from specimen. The 3-organism test included the two most important resistance types for each species.
May 16, 2011 — Initial data from pilot study show strong positive results for the BACcel™ rapid system.
Apr 14, 2011 — Industry collaborator exercises option to extend exclusive negotiation period. Two new presentations at ASM2011.
Mar 01, 2011 — Accelr8 Technology Corporation (NYSE Alternext US: AXK) announced that one of its outside principal investigators received acceptance to present results of a new study in Europe.
Feb 22, 2011 — May meeting for Pulmonary Medicine will have a presentation on preliminary results from study at Denver Health with ICU patient specimens. Company also announced start of product engineering to meet early milestones for next product version.